Executive Officers

Charles L.M. Dunlop

President and Chairman

Charlie is driven by a singular vision: to make genetics a more empowered, collaborative science in order to fulfill the promise of the human genome and help people live healthier, better lives. In 1999, he founded Ambry Genetics because he wanted to work for a company deeply committed to restoring the balance between open science and commercial interests, one driven by pure scientists whose only pursuit is to end disease and provide the best quality service.

For 16 years since the founding of Ambry, Charlie has realized this vision by launching some of the most useful diagnostic tests, and taking on the challenge of eliminating gene patents in the precedent-setting Ambry v. Myriad case, and proceeded to share the company’s genetic data to the public, inviting collaboration with the medical research community and truly putting patients and researchers first. He believes that human life cannot be patented.

Under Charlie’s leadership, the company continues to invest in new technologies, better services, and greater collaboration to transform human health. The company has a long history of many firsts-to-market, including being the first laboratory to provide CLIA-approved exome services for applications in clinical diagnostics. Today, Ambry is the premier clinical molecular diagnostic laboratory and remains led by scientists, offering the most comprehensive suite of genetic testing solutions for inherited and non-inherited diseases.

Two years ago Charlie found he had stage four cancer. Now in remission, Charlie remains deeply connected to the mind and hearts of patients, understanding that access to information is just as important as quality science in finding the best treatment.

Charlie is a graduate of the University of California, San Diego with concentrations in biology, mathematics, physics, economics and history. Prior to starting Ambry, he worked with some of the top academic and commercial laboratories in the world, including the Scripps Research Institute in La Jolla, California. In 2015, Charlie was a recipient of Ernst & Young’s Entrepreneur of the Year award. Along with Ambry, Charlie also founded the Mauli Ola Foundation, a non-profit organization that brings his passion for surfing and the ocean to people living with genetic disorders.

Aaron Elliott, Ph.D.

Chief Executive Officer
Interim Chief Operating Officer, Interim Chief Scientific Officer

Dr. Elliott joined Ambry Genetics in 2008 as a laboratory scientist, working closely on the development of complex molecular diagnostic tests. During his years with the company, Dr. Elliott has held many leadership positions, including Director of Genomic Services, Vice President of Research and Development (R&D), and Chief Scientific Officer.  As a member of the Executive Team, he plays a critical role in product development, quality control, and R&D planning. 

Dr. Elliott began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego, where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation.  As part of this research, Dr. Elliott helped in identifying the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors.

A graduate of Franklin and Marshall College, Dr. Elliott conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine. His thesis involved studying the role of CREB-binding protein in germline and stem cell development.

Jimmy Doss

Chief Commercial Officer

Mr. Doss joined the company in 2016 as Chief Commercial Officer.  In this role, he is responsible for all commercial functions to ensure market development and patient/provider access to our comprehensive suite of genetic testing.  Mr. Doss  is driven by the pursuit of helping to cure all inherited and non-inherited disease and believes that Ambry Genetics is on the path to accomplishing this goal.

Prior to joining the company, Mr. Doss spent more than 16 years at Amgen, one of the world's leading biotechnology companies.  During his time at Amgen, Mr. Doss held several high level positions, including Executive Director of Regional Sales and Executive Director of Marketing, both in Oncology. Throughout his career, Mr. Doss has developed acute knowledge in sales, marketing, management, and commercial operations. 

Mr. Doss received his B.S. degree in Biochemistry from Purdue University.

Chia-Ling Gau, Ph.D.

Laboratory Director

Dr. Gau is certified in clinical molecular genetics by the American Board of Medical Genetics. She graduated with honors from the University of California, Berkeley with a B.A. in Molecular Cell Biology and obtained her Ph.D. in Microbiology, Immunology, and Molecular Genetics from the University of California, Los Angeles (UCLA). She remained at UCLA for her post-doctoral fellowship studying potential gene therapy vectors for treating arginase deficiency. Dr. Gau completed her training in clinical molecular genetics from Cedars Sinai / UCLA Medical Center prior to joining Ambry.

Sharon Mexal, Ph.D.

Director of Clinical Operations

Dr. Mexal graduated with honors from the University of New Mexico with a B.S. in Biology and with a Ph.D. from the Human Medical Genetics Program at the University of Colorado Medical Campus. Dr. Mexal completed her post-doctoral research at the University of Colorado at Boulder Institute for Behavioral Genetics.  Prior to joining Ambry in 2009, she worked as a senior scientist at Cenomed Biosciences, a start-up pharmaceutical company, where she screened novel compounds for anti-psychotic and anti-emetic drug activity. Dr. Mexal has been active in medical genetics research for over a decade and has published numerous articles on the genetics of schizophrenia and tobacco addiction.

Trieu Timothy D. Vo, PhD, DABMG, FACMG

Laboratory Director

Dr. Vo graduated from the University of California, Irvine with a B.S. in Biological Sciences and received his Ph.D. in Molecular Biology and Genetics from Wayne State University. After completing his post-doctoral in the same department, where his work included identifying and characterizing several novel CNS-specific genes located in the 4p16.3 sub-band, Dr. Vo was a clinical fellow in the Detroit Medical Center’s Molecular Genetics Diagnostic Laboratory. While there, he gained experience starting a CLIA-certified molecular laboratory. Dr. Vo was ABMG Board-certified in 1999 and subsequently became the lab’s technical director. He then took a position as a clinical molecular lab director at what was then USLabs, prior to joining Ambry in 2004. Dr. Vo is a Clinical Genetic Molecular Biologist in the state of California and currently holds a COQ in New York state.

Gretchen L. Enright, MBA, CGMBS

Chief Compliance Officer

Gretchen Enright received her undergraduate degree in Biology and Chemistry at Moravian College in Bethlehem, PA, completed medical technology training and received her Master’s degree in Business Administration from Webster University in Irvine, CA. Gretchen is licensed by ASCP and CA state in Molecular Biology and has 17+ years of experience in independent reference laboratories. She most recently worked at Clarient Diagnostics, Inc. a GE Healthcare company where she held Director of Compliance, regulatory affairs and QA roles. Gretchen’s experience has been in somatic and germinal genetic disease testing and regulatory oversight of such testing, as well as regulatory and quality oversight of Pharmaceutical study testing for therapeutic development and targeting. Gretchen initially received her training on the CAS 200 for quantifying DNA in tumor cells at Sacred Heart Hospital in Allentown, PA during her medical technology training, after which she transferred this technology to Nichols Institute (now Quest Diagnostics). She further evolved from immunohistochemistry techniques to molecular pathology and DNA/RNA analysis.